Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages

Stem Cell Research and Therapy

Volumn 4, Issue 6, 2013, Pages

  Ledford, Kelly J ^a   Zeigler, Frank ^a   Bartel, Ronnda L ^a  

^a Aastrom Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CD206 ANTIGEN; CELL MARKER; CHEMOKINE; CYTOKINE; INTERLEUKIN 12; IXMYELOCEL T; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL FUNCTION; CELL ISOLATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFEROCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MACROPHAGE; MONONUCLEAR CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW CELLS; CELLS, CULTURED; HUMANS; INTERLEUKIN-12; LECTINS, C-TYPE; LIPOPOLYSACCHARIDES; MACROPHAGES; MANNOSE-BINDING LECTINS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886736170     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt345     Document Type: Article

References (50)

1. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G, Cell Metab 2007 6 137 143 10.1016/j.cmet.2007.06.010 17681149 (Pubitemid 47189091)
2. New vistas on macrophage differentiation and activation. Mantovani A, Sica A, Locati M, Eur J Immunol 2007 37 14 16 10.1002/eji.200636910 17183610 (Pubitemid 46128780)
3. Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. Jennewein C, Kuhn AM, Schmidt MV, Meilladec-Jullig V, von Knethen A, Gonzalez FJ, Brune B, J Immunol 2008 181 5646 5652 18832723
4. The many faces of macrophage activation. Mosser DM, J Leukoc Biol 2003 73 209 212 10.1189/jlb.0602325 12554797 (Pubitemid 36158295)
5. Gene expression profiling of cutaneous wound healing. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF, J Transl Med 2007 5 11 10.1186/1479-5876-5-11 17313672 (Pubitemid 46351579)
6. Macrophage diversity and polarization in atherosclerosis: a question of balance. Mantovani A, Garlanda C, Locati M, Arterioscler Thromb Vasc Biol 2009 29 1419 1423 10.1161/ATVBAHA.108.180497 19696407
7. Resolution of inflammation: an integrated view. Ortega-Gomez A, Perretti M, Soehnlein O, EMBO Mol Med 2013 5 661 674 10.1002/emmm.201202382 23592557
8. An abundant tissue macrophage population in the adult murine heart with a distinct alternatively-activated macrophage profile. Pinto AR, Paolicelli R, Salimova E, Gospocic J, Slonimsky E, Bilbao-Cortes D, Godwin JW, Rosenthal NA, PLoS One 2012 7 36814 10.1371/journal.pone.0036814 22590615
9. Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. Meznarich J, Malchodi L, Helterline D, Ramsey SA, Bertko K, Plummer T, Plawman A, Gold E, Stempien-Otero A, PLoS One 2013 8 57837 10.1371/journal.pone.0057837 23536772
10. Macrophage plasticity in experimental atherosclerosis. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G, PLoS One 2010 5 8852 10.1371/journal.pone.0008852 20111605
11. Regulation of the inflammatory response in cardiac repair. Frangogiannis NG, Circ Res 2012 110 159 173 10.1161/CIRCRESAHA.111.243162 22223212
12. Human macrophage regulation via interaction with cardiac adipose tissue-derived mesenchymal stromal cells. Adutler-Lieber S, Ben-Mordechai T, Naftali-Shani N, Asher E, Loberman D, Raanani E, Leor J, J Cardiovasc Pharmacol Ther 2013 18 78 86 10.1177/1074248412453875 22894882
13. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Kharraz Y, Guerra J, Mann CJ, Serrano AL, Munoz-Canoves P, Mediators Inflamm 2013 2013 491497 23509419
14. Contrasting Inflammation Resolution during Atherosclerosis and Post Myocardial Infarction at the Level of Monocyte/Macrophage Phagocytic Clearance. Thorp EB, Front Immunol 2012 31 1 8
15. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen CK, Roy S, PLoS One 2010 5 9539 10.1371/journal. pone.0009539 20209061
16. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS, Am J Pathol 2008 172 1112 1126 10.2353/ajpath.2008.070513 18321997 (Pubitemid 351520007)
17. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, Hainzl A, Schatz S, Qi Y, Schlecht A, Weiss JM, Wlaschek M, Sunderkotter C, Scharffetter-Kochanek K, J Clin Invest 2011 121 985 997 10.1172/JCI44490 21317534
18. Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP. Yin D, Wang Z, Gao Q, Sundaresan R, Parrish C, Yang Q, Krebsbach PH, Lichtler AC, Rowe DW, Hock J, Liu P, Mol Ther 2009 17 1967 1978 10.1038/mt.2009.151 19603005
19. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E, Velazquez O, Marston WA, Bartel RL, Longcore A, Stern T, Watling S, J Vasc Surg 2011
20. The Aastrom experience. Bartel RL, Cramer C, Ledford K, Longcore A, Parrish C, Stern T, Watling S, Zeigler F, Stem Cell Res Ther 2012 3 26 10.1186/scrt117 22776246
21. Upper extremity ischemia treated with tissue repair cells from adult bone marrow. Comerota AJ, Link A, Douville J, Burchardt ER, J Vasc Surg 2010 52 723 729 10.1016/j.jvs.2010.04.020 20576396
22. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, Stern TP, Watling S, Bartel RL, Mol Ther 2012 20 1280 1286 10.1038/mt.2012.52 22453769
23. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Gastens MH, Goltry K, Prohaska W, Tschope D, Stratmann B, Lammers D, Kirana S, Gotting C, Kleesiek K, Cell Transplant 2007 16 685 696 18019358 (Pubitemid 351448264)
24. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. Martinez FO, Gordon S, Locati M, Mantovani A, J Immunol 2006 177 7303 7311 17082649 (Pubitemid 44715100)
25. Different responses to oxidized low-density lipoproteins in human polarized macrophages. Hirose K, Iwabuchi K, Shimada K, Kiyanagi T, Iwahara C, Nakayama H, Daida H, Lipids Health Dis 2011 10 1 10.1186/1476-511X-10-1
26. Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. Bories G, Caiazzo R, Derudas B, Copin C, Raverdy V, Pigeyre M, Pattou F, Staels B, Chinetti-Gbaguidi G, Diab Vasc Dis Res 2012 9 189 195 10.1177/1479164111430242 22192929
27. Exploring the full spectrum of macrophage activation. Mosser DM, Edwards JP, Nat Rev Immunol 2008 8 958 969 10.1038/nri2448 19029990
28. Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease. Thorp EB, Apoptosis 2010 15 1124 1136 10.1007/s10495-010-0516-6 20552278
29. Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction. Zizzo G, Hilliard BA, Monestier M, Cohen PL, J Immunol 2012 189 3508 3520 10.4049/jimmunol.1200662 22942426
30. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A, Corraliza I, Mol Endocrinol 2008 22 1394 1402 10.1210/me.2007-0525 18323470 (Pubitemid 351786999)
31. Alternative activation of macrophages. Gordon S, Nat Rev Immunol 2003 3 23 35 10.1038/nri978 12511873 (Pubitemid 37328697)
32. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Laskin DL, Chem Res Toxicol 2009 22 1376 1385 10.1021/tx900086v 19645497
33. Macrophage activation switching: an asset for the resolution of inflammation. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G, Clin Exp Immunol 2005 142 481 489 16297160 (Pubitemid 41719844)
34. Macrophage phenotype as a determinant of biologic scaffold remodeling. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM, Tissue Eng Part A 2008 14 1835 1842 10.1089/ten.tea.2007.0264 18950271
35. Lipopolysaccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by Candida albicans mediated up-regulation of EBI3 expression. Zheng XF, Hong YX, Feng GJ, Zhang GF, Rogers H, Lewis MA, Williams DW, Xia ZF, Song B, Wei XQ, PLoS One 2013 8 63967 10.1371/journal.pone. 0063967 23724011
36. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, PLoS One 2011 6 21874 10.1371/journal.pone.0021874 21799753
37. Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results. Hasan D, Chalouhi N, Jabbour P, Hashimoto T, J Neuroinflammation 2012 9 222 10.1186/1742-2094-9-222 22999528
38. The proinflammatory CD14 + CD16 + DR++ monocytes are a major source of TNF. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L, J Immunol 2002 168 3536 3542 11907116 (Pubitemid 34250422)
39. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Kim J, Hematti P, Exp Hematol 2009 37 1445 1453 10.1016/j.exphem.2009.09.004 19772890
40. IL-10-producing macrophages preferentially clear early apoptotic cells. Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C, Blood 2006 107 4930 4937 10.1182/blood-2005-10-4144 16497970 (Pubitemid 43882647)
41. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE, Arthritis Rheum 2006 54 927 938 10.1002/art.21660 16508977
42. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. Thorp E, Tabas I, J Leukoc Biol 2009 86 1089 1095 10.1189/jlb.0209115 19414539
43. The liaison between apoptotic cells and macrophages-the end programs the beginning. Weigert A, Jennewein C, Brune B, Biol Chem 2009 390 379 390 19335180
44. Alternative activation of macrophages: an immunologic functional perspective. Martinez FO, Helming L, Gordon S, Annu Rev Immunol 2009 27 451 483 10.1146/annurev.immunol.021908.132532 19105661
45. Human Placental Mesenchymal Stem Cells (pMSCs) Play a Role as Immune Suppressive Cells by Shifting Macrophage Differentiation from Inflammatory M1 to Anti-inflammatory M2 Macrophages. Abumaree MH, Al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, Abomaray FM, Fatani AS, Chamley LW, Knawy BA, Stem Cell Rev 2013 9 620 641 10.1007/s12015-013-9455-2 23812784
46. Differentially activated macrophages orchestrate myogenic precursor cell fate during human skeletal muscle regeneration. Saclier M, Yacoub-Youssef H, Mackey AL, Arnold L, Ardjoune H, Magnan M, Sailhan F, Chelly J, Pavlath GK, Mounier R, Kjaer M, Chazaud B, Stem Cells 2013 31 384 396 10.1002/stem.1288 23169615
47. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM, Eur J Vasc Endovasc Surg 2012 44 491 497 10.1016/j.ejvs.2012.08.005 22975154
48. From bench to bedside: review of gene and cell-based therapies and the slow advancement into Phase 3 Clinical Trials, with a focus on Aastrom's Ixmyelocel-T. Bartel RL, Booth E, Cramer C, Ledford K, Watling S, Zeigler F, Stem Cell Rev 2013 9 373 383 10.1007/s12015-013-9431-x 23456574
49. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. van Weel V, van Tongeren RB, van Hinsbergh VW, van Bockel JH, Quax PH, Ann Vasc Surg 2008 22 582 597 10.1016/j.avsg.2008.02.017 18504100
50. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Fadini GP, de Kreutzenberg SV, Boscaro E, Albiero M, Cappellari R, Krankel N, Landmesser U, Toniolo A, Bolego C, Cignarella A, Seeger F, Dimmeler S, Zeiher A, Agostini C, Avogaro A, Diabetologia 2013 56 1856 1866 10.1007/s00125-013-2918-9 23616239